In this episode, Ayesha spoke with Thomas Heineman, MD, PhD, Chief Medical Officer at Oncolytics Biotech, a company developing an oncolytic virus cancer therapeutic that is currently in clinical trials for indications including metastatic breast cancer and pancreatic cancer.

Oncolytics is developing a first-in-class, nonpathogenic oncolytic virus administered intravenously that activates, recruits and trains immune cells to identify and destroy cancer cells. Simultaneously, it remodels the tumor microenvironment, improving immune cell infiltration and access.

Prior to joining Oncolytics, Dr. Heineman held leadership roles at Denovo Biopharma, Genocea Biosciences and Halozyme Therapeutics.

Dr. Heineman’s experience extends to big pharma and academia, as he previously worked as Senior Director, Global Clinical Research and Development at GlaxoSmithKline and as an Associate Professor at the Saint Louis University School of Medicine. Dr. Heineman has co-authored over 60 peer-reviewed publications and is board certified in Internal Medicine and Infectious Diseases.

To hear more about the work Dr. Heineman is leading at Oncolytics Biotech in the development of oncolytic virus therapy, tune into the episode.

For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/

Twitter: https://twitter.com/Xtalks